Teladoc Health stock trades at EUR 5.07 before Xetra opens

Published on 09/30/2026 at 08:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teladoc Health stock posted USD 606.90 million in second-quarter revenue, down 4.00 percent year over year. A legal leadership change takes effect November 2, 2026.

TDOC, US87918A1051, Illustration mit AI erstellt.

Teladoc Health stock (ISIN US87918A1051) was trading at EUR 5.07 at Lang & Schwarz on September 30, 2026 at 8:52 a.m. CEST, down 0.20 percent versus the prior close of EUR 5.08 on September 29, 2026. The company is preparing for a legal leadership transition, with Jonathan Dorfman set to become chief legal officer and secretary on November 2, 2026.

Legal transition sets the news peg

According to GlobeNewswire on September 25, 2026, Adam Vandervoort will resign effective November 1 after 11 years with Teladoc Health. Dorfman, currently senior vice president of securities and corporate law, will succeed him the following day.

The handover gives the market a concrete near-term corporate date, but the larger valuation question remains operational. Teladoc Health serves employers, health plans, health systems and consumers through its virtual-care platform, while BetterHelp remains the more difficult growth area.

BetterHelp weighs on second-quarter figures

Teladoc Health reported second-quarter 2026 revenue of USD 606.90 million, down 4.00 percent from the prior year, and a net loss of USD 38.90 million, or USD 0.21 per diluted share, according to StockTitan in its September 2026 filing summary. Adjusted EBITDA was USD 65.70 million, while operating cash flow reached USD 64.70 million.

The segment split explains the pressure. BetterHelp revenue declined 12.00 percent to USD 212.60 million, whereas Integrated Care revenue rose 1.00 percent to USD 394.30 million and carried a 16.50 percent adjusted EBITDA margin. Full-year 2026 guidance calls for revenue of USD 2.362 billion to USD 2.447 billion and free cash flow of USD 130.00 million to USD 170.00 million.

Analyst target remains above market

According to MarketBeat on September 19, 2026, sixteen research firms carried an average Hold rating, with five Buy ratings, ten Holds and one Sell rating. The average 12-month price target was USD 7.54 against a reported USD 6.32 share price, leaving the analyst view above that dated U.S. market reference.

TDOC enters the session at EUR 5.07

At Lang & Schwarz, Teladoc Health stock was trading at EUR 5.07 on September 30, 2026 at 8:52 a.m. CEST, down 0.20 percent versus the prior close of EUR 5.08. The September 29, 2026 market capitalization was USD 1.0 billion, and the 52-week range was USD 4.40 to USD 9.89.